Andere talen MyMD Pharmaceuticals, Inc.

Aandelen

MYMD

US62856X2018

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,08 ^USD	+6,21%		+20,31%	-60,31%

18/04	MyMD Pharmaceuticals, Inc. kondigt het ontslag aan van Adam Kaplin als Chief Scientific Officer	CI
09/04	Wall Street zal iets hoger openen in afwachting van de inflatiegegevens van woensdag	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

MyMD Pharmaceuticals, Inc. Announces Resignation of Adam Kaplin as Chief Scientific Officer	18/04
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN	10/04
Wall Street Set to Open Slightly Higher as Investors Await Wednesday's Inflation Data	09/04
Investors Eye Wednesday Inflation Data as US Futures Tread Water Tuesday Pre-Bell	09/04
Top Premarket Gainers	09/04
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
MyMD Pharmaceuticals Regains Compliance With Nasdaq's Minimum Bid Listing Requirement	05/03
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing	05/03
MyMD Pharmaceuticals to Implement 1-for-30 Reverse Stock Split	13/02
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing	13/02
MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12
MyMD Pharmaceuticals, Inc. Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis	06/12
MyMD Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Developing a first-in-class small molecule drug for inflammatory disease	09/11
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	20-10-23
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced Acute Inflammatory Pain	19-10-23
Mymd Pharmaceuticals, Inc. Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain	19-10-23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023	05-10-23
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023	04-10-23
MyMD Pharmaceuticals, Inc. to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-a Market Disrupter, at BioFuture 2023	04-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen MyMD Pharmaceuticals, Inc.

Aandelen

MYMD

US62856X2018

Andere talen

Filters